RHRadhwan Mohmmed Hussein

Radhwan Mohmmed Hussein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Radhwan Mohmmed Hussein has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison of clinical characteristics, microvascular complications and inflammatory markers in type 2 diabetic patients under insulin versus metformin treatment: A cross-sectional study at Karbala Diabetic Center, Iraq

    by Haithem Rauf Msc Mohammed, Rym Ben Othman, Hamid Alghurabi, Radhwan M. Hussein, Zaid Al-Obaidi, Haifa Abdesselem

    Type 2 diabetes mellitus (T2DM) is a major global health issue associated with chronic inflammation, which contributes to both disease progression and its complications, including cardiovascular and microvascular disorders. Key inflammatory markers such as tumor necrosis factor-alpha, interleukin-6 (IL-6), E-selectin, and P-selectin are elevated in T2DM patients and are implicated in the development of these complications. Understanding how treatments such as insulin and metformin affect these markers is crucial for improving therapeutic strategies in T2DM. This study investigated the effects of insulin and metformin on these inflammatory markers in T2DM patients. This was a cross-sectional study involving patients with diabetes on insulin (group A), metformin only (group B), and healthy controls (group C). Participants were enrolled from the Diabetic Center in Karbala, Iraq and underwent clinical assessments including ophthalmologic examinations. Fasting blood glucose, HbA1c and lipids levels were assessed. The levels of inflammatory markers (IL-6 and TNF-α), and adhesion molecules (sE-selectin and sP-selectin) were measured using Enzyme-Linked Immunosorbent Assay (ELISA). The study included 522 patients with diabetes: 356 receiving insulin (group A), 70 receiving metformin (group B) and 96 healthy controls (group C). T2DM patients treated with insulin exhibited significantly more microvascular complications than those treated with metformin. Higher rates of retinopathy (64.3% vs 11.4%) and neuropathy (69.9% vs 11.4%) were observed in the insulin group, whereas the incidence of nephropathy did not differ significantly (14.6% vs 11.4%). Inflammatory markers were lower in the insulin group: TNF-α levels were 3-fold lower and IL-6 levels were 8-fold lower. Conversely, sE-selectin levels were 1.5-fold higher in the insulin group, and sP-selectin levels were 1.4-fold higher in the metformin group. This study highlights distinct differences in inflammatory markers and systemic complications between T2DM patients treated with insulin and those treated with metformin alone. Further research is needed to explore the mechanisms underlying these observations and optimize treatment strategies for T2DM patients.


  • Open Access

    Some Biological Markers in Diabetic Patients

    by Ahmed Malk Hassan, Hasan Ali Hussein, Radhwan Mohmmed Hussein, Maryam Hiyder Kadhum

    Endstage renal disease (ESRD) usually comes on by diabetic nephropathy (DN) and is one of the most dreaded chronic microvascular complications of diabetes. The objective of this study is to provide an overview of the DN-biomarker landscape with a particular emphasis on new approaches that improve the sensitivity of biomarkers for identifying patients who will develop DN or who are at risk of developing ESRD. This study was designed as a case-control study. 120 individuals were involved, divided into three groups: a control group diabetic without nephropathy, Early stage and end stage of nephropathy, 40 patients were taken for each group identical in gender (20 male and 20 female). All the diabetic patients included in the current study were diagnosed by nephrologists at the nephrology Clinic at Al-Emam Al Sadeq Hospital in Hila city and Department of Biochemistry in College of Medicine at University of Babylon from October 2022 to March 2023. C-reactive protein was determined by immune-detection method and Vit. D3 by chemiluminescence immunoassay. The results of the current study revealed a significant increase in serum CRP among diabetic nephropathy patients when compared to control and a significant decrease of serum vitamin D3 in diabetic nephropathy patients than control.